Chardan Capital Increases Earnings Estimates for Prothena

Key Points

• Chardan Capital has raised its FY2026 earnings per share estimate for Prothena to $4.00, significantly up from a previous estimate of ($3.55), with a current "Buy" rating and a target price of $18.00.
• Prothena's recent quarterly earnings report revealed an EPS of (1.86), falling short of expectations by ($0.75), with revenues also below estimates.
• Institutional investors hold 97.08% of Prothena's stock, indicating significant institutional interest and involvement in the company's equity.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Research analysts at Chardan Capital raised their FY2026 EPS estimates for shares of Prothena in a research note issued to investors on Tuesday, August 5th. Chardan Capital analyst R. Li now anticipates that the biotechnology company will post earnings per share of $4.00 for the year, up from their prior estimate of ($3.55). Chardan Capital has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Several other research analysts have also recently issued reports on PRTA. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Prothena in a report on Tuesday, August 5th. Piper Sandler decreased their price objective on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday, May 27th. Jefferies Financial Group lowered shares of Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target for the company. in a research report on Tuesday, May 27th. JMP Securities reduced their price target on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 27th. Finally, Oppenheimer cut shares of Prothena from an "outperform" rating to a "market perform" rating in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $30.25.

Prothena Trading Down 1.7%

Shares of NASDAQ PRTA traded down $0.13 during mid-day trading on Friday, reaching $7.54. The company had a trading volume of 906,550 shares, compared to its average volume of 1,063,669. The business's 50-day moving average is $6.26 and its 200-day moving average is $9.54. The stock has a market cap of $405.88 million, a price-to-earnings ratio of -1.34 and a beta of -0.03. Prothena has a 52 week low of $4.32 and a 52 week high of $22.83.

Prothena (NASDAQ:PRTA - Get Free Report) last released its earnings results on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.75). The company had revenue of $4.42 million during the quarter, compared to analysts' expectations of $5.36 million. Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.

Hedge Funds Weigh In On Prothena

A number of institutional investors have recently made changes to their positions in the business. Deutsche Bank AG raised its position in shares of Prothena by 195.7% during the 4th quarter. Deutsche Bank AG now owns 95,970 shares of the biotechnology company's stock valued at $1,329,000 after acquiring an additional 63,512 shares in the last quarter. Barclays PLC boosted its stake in Prothena by 10.6% during the fourth quarter. Barclays PLC now owns 105,338 shares of the biotechnology company's stock valued at $1,458,000 after buying an additional 10,116 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Prothena during the first quarter valued at about $126,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Prothena in the fourth quarter worth approximately $1,117,000. Finally, SG Americas Securities LLC grew its holdings in shares of Prothena by 92.9% during the first quarter. SG Americas Securities LLC now owns 72,559 shares of the biotechnology company's stock valued at $898,000 after buying an additional 34,947 shares in the last quarter. 97.08% of the stock is owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.